Sanofi (ENXTPA:SAN) Is Up 5.7% After Dupixent’s Positive Phase 3 Results in AFRS—What's Changed

Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...
Medscape

Monoclonal Antibodies and JAK Inhibitors Effective for Rare Photosensitive Skin Disorders

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a ...